The development of rapamycin as an orphan drug

Clinical Advances in Hematology and Oncology

Volumn 5, Issue 2, 2007, Pages 99-100

  Hidalgo, Manuel ^a  

^a JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; ORPHAN DRUG; RAPAMYCIN; TEMSIROLIMUS; THALIDOMIDE;

ANTIMICROBIAL ACTIVITY; ANTINEOPLASTIC ACTIVITY; ARTICLE; CLINICAL TRIAL; DRUG EFFICACY; DRUG INHIBITION; DRUG RESEARCH; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; PANCREAS CANCER; POSITRON EMISSION TOMOGRAPHY; RECOMMENDED DRUG DOSE; SINGLE DRUG DOSE;

CLINICAL TRIALS, PHASE I; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; MALE; ORPHAN DRUG PRODUCTION; PANCREATIC NEOPLASMS; PROTEIN KINASES; SIROLIMUS; TREATMENT OUTCOME;

EID: 33947416563     PISSN: 15430790     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (4)

1. Abraham RT. Mammalian target of rapamycin: immunosuppressive drugs uncover a novel pathway of cytokine receptor signaling. Curr Opin Immunol. 1998;10: 330-336.
2. Cohen E. mTOR inhibitors. Clin Adv Hematol Oncol. 2006;4:38-39.
3. Jimeno J, Kulesza P, Cusatis G, et al. Pharmacodynamic-guided, modified continuous reassessment method (mCRM)-based, dose finding study of rapamycin in adult patients with solid tumors. J Clin Oncol. 2006;24(18S): Abstract 3020.
4. Hidalgo M, Rubio-Viqueira B, Weekes C, et al. In vivo platform for translational drug development and biomarker discovery in pancreatic cancer. J Clin Oncol. 2006;24(18S): Abstract 4000.